Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424446 · ClinicalTrials.gov registry record
Saliva as Source of Detection for SARS-CoV-2
A clinical trial of COVID-19, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 456
- Enrollment target
- 2
- Study locations
NCT04424446 is a study of COVID-19 that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 456 participants, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04424446, a study of COVID-19, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 456 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Nasopharyngeal (NP) swabbing is being used to test for SARS-CoV-2 infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. Researchers want to find an easier way to collect samples. Objective: To learn if testing for SARSCoV-2 with a saliva sample only, a nasal swab from just the front part of the nostril only, or a saliva sample plus a nasal swab gives results that are as accurate as the NP swab. Eligibility: NIH staff members age 18 and older who are taking part in NIH CC SARS-CoV-2 surveillance. Design: The Occupational Medical Service (OMS) collects NP swabs as part of standard NIH staff screening. Participants will give 1 or 2 saliva samples and 1 or 2 nasal swabs when their NP swab is collected by OMS. If their NP swab was already collected, their OMS record will be reviewed for the result. If the NP swab result is positive, the participant will have another NP swab. At that time, they will also give 1 or 2 saliva samples and 1 or 2 nasal swabs. If the NP swab result is negative, they will give 1 or 2 saliva samples and 1 or 2 nasal swabs the next time they have an NP swab. For the saliva sample, participants will spit into a tube. For the nasal swab, the inside of the front part of the nostril will be swabbed. Participation ends after the study samples are collected. Participants can choose to keep giving saliva and nasal swab samples each time they have an NP swab.
Conditions Studied
Study Locations (2)
District of Columbia
- Washington Hospital Center - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2020-09-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424446
The ClinicalTrials.gov registry entry for NCT04424446 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04424446 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT04424446 about?
NCT04424446 is a clinical study titled "Saliva as Source of Detection for SARS-CoV-2". Background: Nasopharyngeal (NP) swabbing is being used to test for SARS-CoV-2 infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. Researchers want to find an easier way to collect samples. Objective: To learn if test...
What is the current status of trial NCT04424446?
This trial is currently completed. The enrollment target is 456 participants. The study started on 2020-07-13. Estimated completion is 2020-09-04.
What conditions does trial NCT04424446 study?
This clinical trial studies the following conditions: COVID-19.
Who is sponsoring clinical trial NCT04424446?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04424446 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.